NDATOPICALGEL
Approved
Oct 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
VOLTAREN ARTHRITIS PAIN (diclofenac sodium) by GSK is (ak) is unknown. First approved in 2007.
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOLTAREN ARTHRITIS PAIN is a topical gel formulation of diclofenac sodium, a nonsteroidal anti-inflammatory drug (NSAID) approved in 2007 for localized arthritis pain relief. The mechanism of action is classified as unknown in the data, though diclofenac typically works by inhibiting cyclooxygenase (COX) enzymes to reduce inflammation and pain. This product targets patients seeking non-systemic pain management for osteoarthritis and other joint conditions.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching, signaling reduced team investment and potential consolidation or restructuring within the brand portfolio.
Mechanism of Action
(AK) is unknown.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy of Diclofenac Sodium Shock Wave Phonophoresis on Patients With Subacromial Impingement Syndrome
Started Jun 2026
70 enrolled
Shock WaveSubacromial Impingement Syndrome
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
Started Oct 2022
447 enrolled
Keratosis, Actinic
To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain.
Started Jan 2021
110 enrolled
Postural Low Back PainMechanical Low Back Pain
A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee"
Started May 2017
1,220 enrolled
Osteoarthritis, Knee
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp
Started Oct 2015
492 enrolled
Actinic Keratosis
Worked on VOLTAREN ARTHRITIS PAIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.